Evidence map›Paper›PMID 24038328›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2014

MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.

Elisa Benasciutti, Elisabetta Mariani, Laura Oliva, Maria Scolari, Egon Perilli, Emmanuele Barras, Enrico Milan, Ugo Orfanelli, Nicola L Fazzalari, Lara Campana and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Hormone sensitive lipase ablation promotes bone regeneration.Biochimica et biophysica acta. Molecular basis of disease · 2022
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. CIITA: a master regulator of adaptive immunity shows its innate side in the bone.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 4 countries.

Elisa BenasciuttiDivision of Genetics and Cell Biology and BoNetwork, DiBiT, San Raffaele Scientific Institute, Milano, Italy; Università Vita-Salute San Raffaele, Milano, Italy.
Elisabetta Mariani
Laura Oliva
Maria Scolari
Egon Perilli
Emmanuele Barras
Enrico Milan
Ugo Orfanelli
Nicola L Fazzalari
Lara Campana
Annalisa Capobianco
Luc Otten
Francesca Particelli
Hans Acha-Orbea
Fabio Baruffaldi
Roberta Faccio
Roberto Sitia
Walter Reith
Simone Cenci
Vita-Salute San Raffaele University · ITSouth Australia Pathology · AUUniversity of Geneva · CHUniversity of Lausanne · CHIstituto Ortopedico Rizzoli · ITMedica (Italy) · ITWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular networks controlling bone homeostasis are not fully understood. The common evolution of bone and adaptive immunity encourages the investigation of shared regulatory circuits. MHC Class II Transactivator (CIITA) is a master transcriptional co-activator believed to be exclusively dedicated for antigen presentation. CIITA is expressed in osteoclast precursors, and its expression is accentuated in osteoporotic mice. We thus asked whether CIITA plays a role in bone biology. To this aim, we fully characterized the bone phenotype of two mouse models of CIITA overexpression, respectively systemic and restricted to the monocyte-osteoclast lineage. Both CIITA-overexpressing mouse models revealed severe spontaneous osteoporosis, as assessed by micro-computed tomography and histomorphometry, associated with increased osteoclast numbers and enhanced in vivo bone resorption, whereas osteoblast numbers and in vivo bone-forming activity were unaffected. To understand the underlying cellular and molecular bases, we investigated ex vivo the differentiation of mutant bone marrow monocytes into osteoclasts and immune effectors, as well as osteoclastogenic signaling pathways. CIITA-overexpressing monocytes differentiated normally into effector macrophages or dendritic cells but showed enhanced osteoclastogenesis, whereas CIITA ablation suppressed osteoclast differentiation. Increased c-fms and receptor activator of NF-κB (RANK) signaling underlay enhanced osteoclast differentiation from CIITA-overexpressing precursors. Moreover, by extending selected phenotypic and cellular analyses to additional genetic mouse models, namely MHC Class II deficient mice and a transgenic mouse line lacking a specific CIITA promoter and re-expressing CIITA in the thymus, we excluded MHC Class II expression and T cells from contributing to the observed skeletal phenotype. Altogether, our study provides compelling genetic evidence that CIITA, the molecular switch of antigen presentation, plays a novel, unexpected function in skeletal homeostasis, independent of MHC Class II expression and T cells, by exerting a selective and intrinsic control of osteoclast differentiation and bone resorption in vivo.

Indexed as

AnimalsAntigen PresentationCell DifferentiationGene Expression RegulationHistocompatibility Antigens Class IIMiceMice, KnockoutNuclear ProteinsOsteoclastsReceptor, Macrophage Colony-Stimulating FactorT-LymphocytesTrans-ActivatorsHistocompatibility Antigens Class IIMHC class II transactivator proteinNuclear ProteinsReceptor, Macrophage Colony-Stimulating FactorTrans-ActivatorsADAPTIVE IMMUNITYBONECIITAMHC CLASS IIOSTEOCLAST DIFFERENTIATION

Identifiers

PMID24038328
OpenAlexW2091664853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.